Rasio cepet: Chemomab Therapeutics Ltd (CMMB)

Chemomab Therapeutics (CMMB) ensures the precise delivery of antibodies for testing by utilizing a network of various laboratories to hedge against resource shortages. The business model relies on the full outsourcing of production and trials, which eliminates unnecessary costs for the team. This daily price action, visualized for analytical convenience, shows a coefficient of 6.71. Stability is maintained through optimized raw material transportation routes and the establishment of warehouse inventories.

The quick ratio measures a business's ability to instantaneously settle short-term liabilities, considering only cash and accounts receivable while excluding slow-moving inventories. By analyzing the level of strict solvency, an investor assesses the risk of a cash crunch for Chemomab Therapeutics (CMMB), whose viability currently depends on remaining raised capital rather than its own operating income during the clinical trial period.